A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)

I1F-MC-RHBV -

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in participants with radiographic axial spondyloarthritis (rad-axSpA) who have never taken biological disease-modifying anti-rheumatic drugs (bDMARDs).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Spondyloarthritis
What the trial is testing?
Adalimumab, Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
341
Trial Dates
May 2, 2016 - Oct 17, 2018
How long will I be in the trial?
Your participation could last up to 20 months and include 15 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.